View Exam | PowerPak

1. The analgesic activity of most opioid analgesics is primarily attributed to which of the following?

A. Mu opioid receptor agonism B. Delta opioid receptor agonism C. Kappa opioid receptor agonism D. Delta opioid receptor antagonism E. Unsure

2. A new abuse-deterrent formulation of oral extended-release oxycodone contains inactive ingredients that make it more difficult to crush, chew, or break. This is an example of which of the following abuse deterrence mechanisms?

A. Agonist/antagonist combination B. Aversion C. Physical/chemical barriers D. Prodrug with intrinsic abuse-deterrent properties E. Unsure

3. A 32-year-old male with a history of ongoing recreational opioid use presents to the emergency room with traumatic injuries from a car accident. He has no other medical history, and he is currently in severe pain. Which of the following opioid analgesics would be most appropriate to treat his pain?

A. Buprenorphine B. Hydromorphone C. Codeine D. Extended-release oxycodone E. Unsure

4. A 56-year-old female with no history of opioid use is starting opioid therapy to treat chronic cancer pain. She has dysphagia and cannot swallow whole tablets. Which of the following would be most appropriate for initial therapy in this patient?

A. Morphine extended-release capsule 30 mg orally every 24 hours B. Morphine oral solution 15 mg orally every 4 hours C. Morphine extended-release tablet 30 mg orally every 12 hours D. Morphine immediate-release tablet 15 mg orally every 4 hours E. Unsure

5. Which of the following represents appropriate dosing and administration instructions for a patient prescribed a fentanyl transdermal patch?

A. Apply patch to chest, back, flank, or upper arm every 24 hours; rotate application sites B. Apply patch to chest or upper arm every 72 hours; use the same application site each time C. Apply patch to chest, back, flank, or upper arm every 24 hours; avoid exposing the patch to external heat sources D. Apply patch to chest, back, flank, or upper arm every 72 hours; rotate application sites and avoid exposing the patch to external heat sources E. Unsure

6. Which of the following opioid analgesics is a mu opioid receptor agonist and an N-methyl-D-aspartate (NMDA) antagonist?

A. Oxycodone B. Buprenorphine C. Tramadol D. Methadone E. Unsure

7. Which of the following is an example of a Category 3 abuse deterrence study?

A. Researchers attempt to crush or grind an abuse-deterrent tablet using a variety of different methods and tools to test the ease of mechanical manipulation B. The pharmacokinetics of intact and manipulated abuse-deterrent tablets are compared to the pharmacokinetics of intact and manipulated comparator formulations C. Recreational opioid users rate their overall level of “drug liking” for the abuse-deterrent and comparator formulations D. Data from various sources are used to assess real-world levels of abuse and overdose associated with an approved abuse-deterrent formulation E. Unsure

8. Which of the following opioid analgesics is NOT available in an extended-release abuse-deterrent formulation?

A. Oxymorphone B. Oxycodone C. Hydrocodone D. Morphine E. Unusure

9. A patient has been prescribed hydrocodone/acetaminophen tablets for pain. Each tablet contains 5 mg hydrocodone and 325 mg acetaminophen. What is the maximum number of hydrocodone/acetaminophen tablets this patient can take per day?

A. 6 tablets B. 9 tablets C. 12 tablets D. There is no maximum if the dose is appropriately titrated E. Unsure

10. A 67-year-old female with metastatic breast cancer presents for a follow-up appointment at the pain management clinic. She is currently taking extended-release oxycodone tablets 30 mg every 12 hours. For the most part, her pain is controlled on her current regimen, but she sometimes experiences episodes of severe breakthrough pain. Which opioid analgesic formulation would be the most appropriate choice to treat these episodes of severe breakthrough pain?

A. Morphine immediate-release oral tablet B. Fentanyl sublingual tablet C. Sufentanil sublingual tablet D. Tramadol immediate-release oral tablet E. Unsure

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. The analgesic activity of most opioid analgesics is primarily attributed to which of the following?

2. A new abuse-deterrent formulation of oral extended-release oxycodone contains inactive ingredients that make it more difficult to crush, chew, or break. This is an example of which of the following abuse deterrence mechanisms?

4. A 56-year-old female with no history of opioid use is starting opioid therapy to treat chronic cancer pain. She has dysphagia and cannot swallow whole tablets. Which of the following would be most appropriate for initial therapy in this patient?

5. Which of the following represents appropriate dosing and administration instructions for a patient prescribed a fentanyl transdermal patch?

6. Which of the following opioid analgesics is a mu opioid receptor agonist and an N-methyl-D-aspartate (NMDA) antagonist?

7. Which of the following is an example of a Category 3 abuse deterrence study?

8. Which of the following opioid analgesics is NOT available in an extended-release abuse-deterrent formulation?

9. A patient has been prescribed hydrocodone/acetaminophen tablets for pain. Each tablet contains 5 mg hydrocodone and 325 mg acetaminophen. What is the maximum number of hydrocodone/acetaminophen tablets this patient can take per day?

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. The analgesic activity of most opioid analgesics is primarily attributed to which of the following?

2. A new abuse-deterrent formulation of oral extended-release oxycodone contains inactive ingredients that make it more difficult to crush, chew, or break. This is an example of which of the following abuse deterrence mechanisms?

4. A 56-year-old female with no history of opioid use is starting opioid therapy to treat chronic cancer pain. She has dysphagia and cannot swallow whole tablets. Which of the following would be most appropriate for initial therapy in this patient?

5. Which of the following represents appropriate dosing and administration instructions for a patient prescribed a fentanyl transdermal patch?

6. Which of the following opioid analgesics is a mu opioid receptor agonist and an N-methyl-D-aspartate (NMDA) antagonist?

7. Which of the following is an example of a Category 3 abuse deterrence study?

8. Which of the following opioid analgesics is NOT available in an extended-release abuse-deterrent formulation?

9. A patient has been prescribed hydrocodone/acetaminophen tablets for pain. Each tablet contains 5 mg hydrocodone and 325 mg acetaminophen. What is the maximum number of hydrocodone/acetaminophen tablets this patient can take per day?

« Return to Activity

Customers who Purchased
this Activity also Purchased